Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Arie Belldegrun
Age : 71
Public asset : 41,553,357 USD
Country of residence : Unknown
Linked companies : Ginkgo Bioworks Holdings, Inc. - Allogene Therapeutics, Inc. - Kronos Bio, Inc. - UroGen Pharma Ltd.

Biography of Arie Belldegrun 
Arie S. Belldegrun is an entrepreneur and businessperson who founded 6 companies, among them: Kite Pharma, Inc., Allogene Therapeutics, Inc. and Agensys, Inc. and who has been at the head of 16 different companies. Presently, he holds the position of Chairman & Partner at Two River Group Holdings LLC, Chairman for Two River Group Management LLC, Chairman at Bellco Capital LLC (which he founded in 2003), Chairman at Two Rivers Consulting Corp., Chairman for UroGen Pharma Ltd., Chairman & Partner at Two River Consulting LLC, Executive Chairman of Allogene Therapeutics, Inc. (which he founded in 2017), Chairman of Kronos Bio, Inc., Co-Chairman at Breakthrough Properties LLC, Senior Managing Director at VV Manager LLC (which he founded in 2017), Senior Managing Director at Vida Ventures LLC (which he founded in 2017) (a subsidiary of VV Manager LLC) and Chairman of Technology Assessment Group. Arie S. Belldegrun is also Director & Professor at UCLA Institute of Urologic Oncology, Head-Urologic Oncology Division at David Geffen School of Medicine and Senior Managing Director at Vida Ventures LLC (he founded the company in 2017) and on the board of 5 other companies. Dr. Belldegrun previously was Chairman of Arno Therapeutics, Inc. and Non-Executive Chairman at Arno Therapeutics, Inc. (a subsidiary of Arno Therapeutics, Inc.), Chairman, President & Chief Executive Officer at Equinor ASA, Director at Agensys, Inc. (he founded the company in 1997), Executive Chairman, President & CEO at Kite Pharma, Inc. (he founded the company in 2009), Chairman-Molecular Biological Technology Committee at American Urological Association Education & Research, Inc., Researcher at National Cancer Institute and Member of Los Angeles Economy & Jobs Committee. Arie S. Belldegrun received a doctorate from The Hebrew University Hadassah Medical School and a graduate degree from Weizmann Institute of Science.


Current positions of Arie Belldegrun 
Holdings of Arie Belldegrun 
Arie Belldegrun : Personal Network 
Most Read News 
05/20XAVIER NIEL : UWR shares spike as billionaire Xavier Niel discloses 27% stake
RE
05/14ELON MUSK : Elon Musk says Twitter legal team told him he violated an NDA
RE
05/24ELON MUSK : In a faceoff with Elon Musk, the SEC blinked
RE
05/19ELON MUSK : Musk says 'Tesla is on my mind 24/7' amid concerns about Twitter distraction
RE
05/17ELON MUSK : Prominent hedge funds invested in Twitter before Musk unveiled plans
RE
05/25ELON MUSK : Twitter investors vote against re-electing Elon Musk ally to board
RE
05/27ELON MUSK : Musk sued by Twitter investors for stock 'manipulation' during takeover bid
RE
05/23HOCK TAN : Chipmaker Broadcom in talks to acquire VMware for $60 billion -sources
RE
05/17JPMorgan shareholders vote disapproval of CEO Dimon's special payout
RE
05/20LUCA DE MEO : Renault boss Luca de Meo could return to Japan in June - source
RE
More news


© 2022 People and Ownership :   
Arie Belldegrun : Connections 


Latest news about Arie Belldegrun 
01/14INSIDER BUY : Allogene Therapeutics
MT
01/13TRANSCRIPT : UroGen Pharma Ltd. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-13-2022 09:45 AM
CI
2021TRANSCRIPT : Ginkgo Bioworks Holdings, Inc., Q3 2021 Earnings Call, Nov 15, 2021
CI
2021TRANSCRIPT : UroGen Pharma Ltd. - Special Call
CI
2021Ginkgo Bioworks, Inc. completed the acquisition of Soaring Eagle Acquisition Corp. from Eagle Equity Partners III, LLC and others.
CI
2021TRANSCRIPT : Ginkgo Bioworks, Inc., Soaring Eagle Acquisition Corp. - Pre Recorded M&A Call
CI
2021Ginkgo Bioworks, Inc. entered into definitive agreement to acquire Soaring Eagle Acquisition Corp. from Eagle Equity Partners III, LLC and others for $16.7 billion in a reverse merger transaction.
CI
More news